ClinicalTrials.Veeva

Menu

Accuracy of Convex Probe EBUS-TBNA Versus FDG-PET/CT Imaging in Diagnosis and Staging of Lung Malignancies

A

Ain Shams University

Status

Completed

Conditions

Mediastinal Lymphadenopathy
Lung Malignancies

Treatments

Diagnostic Test: Endo bronchial ultrasound transbronchial needle aspiration(EBUS-TBNA)

Study type

Interventional

Funder types

Other

Identifiers

NCT06479798
department of chest diseases

Details and patient eligibility

About

Lung cancer is a prevalent cause of cancer-related mortality on a global scale. Appropriate staging of lung cancer is of paramount importance, as it customizes treatment and predicts prognosis. Fludeoxyglucose-18 (FDG) positron emission tomography (PET) combined with low dose contrast computed tomography (CT) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) are two diagnostic modalities widely used in the field of staging & diagnosis of lung malignancies, the former depends on image analysis while the later enables real-time sampling of lymph nodes under sonographic guidance with concurrent cytological examination. The present research aims to compare the diagnostic and staging accuracies of (EBUS-TBNA) versus FDG-PET /CT as two diagnostic modalities in patients with suspected lung malignancies. However as a secondary outcome this study aims at monitoring the possible complications arising post EBUS-TBNA procedure.

Full description

Lung cancer is a prevalent cause of cancer-related mortality on a global scale. Appropriate staging of lung cancer is of paramount importance, as it customizes treatment and predicts prognosis. Fludeoxyglucose-18 (FDG) positron emission tomography (PET) combined with low dose contrast computed tomography (CT) and endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) are two diagnostic modalities widely used in the field of staging & diagnosis of lung malignancies, the former depends on image analysis while the later enables real-time sampling of lymph nodes under sonographic guidance with concurrent cytological examination.

Objective: To compare the diagnostic and staging accuracy of convex probe EBUS-TBNA versus FDG - PET/CT as two diagnostic modalities in diagnosis of suspected lung cancer & staging of concurrent mediastinal lymphadenopathy Patients and Methods: This prospective, interventional cohort research was performed on 40 cases with suspected lung malignancies. All cases were examined via FDG-PET/CT followed by convex probe EBUS-TBNA for diagnosis of suspected lung cancer & staging of concurrent mediastinal lymphadenopathy.

Enrollment

40 patients

Sex

All

Ages

18 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients 18 years old or more.
  • Patients presented with centrally located suspiciously malignant lung masses with or without lymphadenopathy.
  • patients with mediastinal lymphadenopathy only as evident by contrast - enhanced CT scan of the chest.
  • patients with peripheral lung malignancy and mediastinal lymphadenopathy who were referred for MLN staging were also recruited to the research

Exclusion criteria

  • All patients who were who were unfit for bronchoscopy as per international guidelines for practice.
  • Cases are diagnosed with stage IV (metastatic) lung cancer.
  • Patients with histopathological diagnosis other than malignancy (as Sarcoidosis, Tuberculosis).
  • patients unfit for FDG-PET G-PET/CT examination (uncontrolled Hyperglycemia, renal impairment).
  • Patients who refused to participate to the study.

Trial design

Primary purpose

Diagnostic

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

40 participants in 1 patient group

FDG PET and EBUS TBNA arm
Other group
Description:
It is a single arm in which all patients undergo FDG PET and EBUS-TBNA
Treatment:
Diagnostic Test: Endo bronchial ultrasound transbronchial needle aspiration(EBUS-TBNA)

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems